This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idera Pharmaceuticals Presents Preclinical Data On Its Gene-silencing Oligonucleotides (GSOs) At EuroTIDES 2011 Conference

Stocks in this article: IDRA

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new data on its novel gene-silencing oligonucleotide (GSO) technology at the 12 th annual EuroTIDES conference being held in Berlin, Germany November 15-16, 2011. The preclinical data demonstrated that GSOs exert target-specific gene-silencing activity following systemic delivery and, due to their novel structure, minimize the sequence-dependent immune stimulation that is associated with other approaches to gene-silencing.

“We are very pleased to have observed that the novel structure of GSOs, in which the five-prime end is not accessible, minimizes immune stimulation,” commented Nicola La Monica, Ph.D., Vice President of Biology at Idera Pharmaceuticals. “The immune stimulatory effects of other gene-silencing approaches have resulted in off-target effects that may interfere with the intended mechanism of action or have other unintended consequences. GSOs provide a potential approach for gene-silencing following systemic delivery with reduced off-target effects.”

The data presented are from preclinical studies evaluating the gene silencing activity of GSOs targeted to various messenger RNA targets. The GSOs were administered systemically to mice, without the use of any delivery technology. The GSOs showed significant specific gene-silencing activity as monitored by suppression of targeted RNA and protein. For comparison, a number of antisense sequences were evaluated for in vivo immune activation, as monitored by circulating cytokines. The data showed that GSOs minimized the induction of immune responses compared to antisense oligonucleotides. GSOs are single-stranded oligonucleotides with two exposed 3’-ends and 5’-ends that are not accessible. It has been shown that accessibility of the 5’-ends of oligonucleotides maximizes immune activation.

The presentation entitled “ Gene-silencing oligonucleotides: Innovative design of oligonucleotides with enhanced efficacy and RNAi-like mechanism of action” was presented by Nicola La Monica of Idera Pharmaceuticals.

About Gene-silencing Oligonucleotides

Idera's gene-silencing oligonucleotides (GSOs) are single-stranded RNA or DNA constructs with two exposed 3'-ends that are complementary to targeted mRNA sequences of therapeutic interest. In preclinical studies, GSOs have inhibited gene expression in vivo without requiring a delivery enhancement technology. Idera has filed multiple patent applications for its GSOs that are pending in many countries around the world.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs